Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 3, 2012, Pages 308-314

  Murad, John P ^a   Espinosa, Enma V P ^a   Ting, Harold J ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

angiotensin receptor; anithrombotic agents; antagonist; antiplatelet agents; drug repurposing; hypertension; losartan; platelet activation; thrombosis; thromboxane A2 receptor

Indexed keywords

ADENOSINE DIPHOSPHATE; LOSARTAN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CAROTID ARTERY INJURY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; EX VIVO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOSIS PREVENTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARACHIDONIC ACID; BLOOD COAGULATION; CAROTID ARTERY INJURIES; LOSARTAN; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOSIS;

EID: 84865148939     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411425491     Document Type: Article

References (31)

1. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011 ; 364 (18). 1746-1760
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med.. 1980 ; 303 (16). 897-902 (Pubitemid 10021186)
3. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb.. 2011 ; 18 (6). 431-442
4. Coccheri S. Antiplatelet drugs-do we need new options?. With a reappraisal of direct thromboxane inhibitors. Drugs. 2010 ; 70 (7). 887-908
5. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res.. 2006 ; 99 (12). 1293-1304 (Pubitemid 44949665)
6. Stanton B. Fifty years ago in the journal of pediatrics: editor's column: the story of aspirin. J Pediatr.. 2007 ; 150 (3). 246-246
7. Matsuno H, Uematsu T, Niwa M, et al. Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol.. 2002 ; 42 (7). 782-790 (Pubitemid 34663535)
8. Mehta A, Mehta D, Loganathan J, Paladugu N, Bhalodkar NC. Clopidogrel with proton pump inhibitors: safe or not?. Clin Cardiol.. 2011 ; 34 (9). 528-531
9. Ting HJ, Murray WJ, Khasawneh FT. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane a(2) receptor. Acta Pharmacol Sin.. 2010 ; 31 (2). 150-159
10. Ting HJ, Khasawneh FT. Glybenclamide: an antidiabetic with in vivo antithrombotic activity. Eur J Pharmacol.. 2010 ; 649 (1-3). 249-254
11. Ch?opicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves txa2 receptor antagonism but not txa2 synthase inhibition. J Physiol Pharmacol.. 2000 ; 51 (4 pt 1). 715-722 (Pubitemid 32049523)
12. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens.. 1999 ; 17 (3). 447-452 (Pubitemid 29116654)
13. Bird JE, Smith PL, Bostwick JS, Shipkova P, Schumacher WA. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (pi3k)-[beta] inhibitor in mice. Thromb Res.. 2011 ; 127 (6). 560-564
14. ?ukawski K, Janowska A, Jakubus T, Tochman-Gawda A, Czuczwar SJ. Angiotensin at1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur J Pharmacol.. 2010 ; 640 (1-3). 172-177
15. Chabielska E, Pawlak R, Golatowski J, Ró?kowski R, Pawlak D, Buczko W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res.. 1998 ; 90 (6). 271-278 (Pubitemid 28383788)
16. Kaminska M, Mogielnicki A, Stankiewicz A, et al. Angiotensin II via at1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol.. 2005 ; 56 (4). 571-585 (Pubitemid 43127554)
17. Ablooglu AJ, Kang J, Petrich BG, Ginsberg MH, Shattil SJ. Antithrombotic effects of targeting alphaiibbeta3 signaling in platelets. Blood.. 2009 ; 113 (15). 3585-3592
18. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem.. 2005 ; 280 (45). 37430-37438 (Pubitemid 41642350)
19. Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane a2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther.. 1997 ; 281 (13). 1065-1070 (Pubitemid 27258361)
20. Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II at(1) receptor antagonist irbesartan prevents thromboxane a(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther.. 2000 ; 292 (1). 238-246 (Pubitemid 30026376)
21. Taketo M, Rochelle JM, Sugimoto Y, et al. Mapping of the genes encoding mouse thromboxane a2 receptor and prostaglandin e receptor subtypes ep2 and ep3. Genomics.. 1994 ; 19 (3). 585-588 (Pubitemid 24071338)
22. Nunez A, Gomez J, Zalba LR, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst.. 2000 ; 1 (2). 175-179
23. Serebruany VL, Pokov AN, Malinin AI, et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: valsartan inhibits platelets (vip) trial. Am Heart J.. 2006 ; 151 (1). 92-99 (Pubitemid 41815336)
24. Tanaka T, Sato R, Kurimoto T. Z-335, a new thromboxane a(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur J Pharmacol.. 2000 ; 401 (3). 413-418 (Pubitemid 30608727)
25. KimJ-SLeeK-SKimY-ITamaiYNakahataRTakamiH.A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci.Aug2004;11(6):600-602. (Pubitemid 38916968)
26. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med.. 2010 ; 10: 1-8
27. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. Accf/aha clopidogrel clinical alert: Approaches to the fda "boxed warning": a report of the american college of cardiology foundation task force on clinical expert consensus documents and the american heart association endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol.. 2010 ; 56 (4). 321-341
28. Price M, Schueler A. Understanding clopidogrel's interaction with cyp2c19 inhibitors. J Nurse Pract.. 2010 ; 6 (9). 715-720
29. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet.. 2005 ; 44 (8). 797-814 (Pubitemid 41126929)
30. Kappert K, Tsuprykov O, Kaufmann J, et al. Chronic treatment with losartan results in sufficient serum levels of the metabolite exp3179 for PPARgamma activation. Hypertension.. 2009 ; 54 (4). 738-743
31. Bousser MG, Amarenco P, Chamorro A, Fisher M, et al. PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (perform): a randomised, double-blind, parallel-group trial. Lancet. 2011 ; 377 (9782). 2013-2022